Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis
Authors' conclusion
Our scRNA-seq studies revealed key differences in the transcriptomic features of CBG-treated and CBG-untreated PRLomas in both tumor and microenvironment cellular constituents, and for the first time, describe the previously unknown activation of CD8+ T cells following CBG treatment, which may play a role in the tumoricidal actions of CBG.
Study context
- Population
- Surgically resected human prolactinomas (PRLomas) and neighboring stromal and immune cells5 resected PRLomas
- Participants
- 5 participants
- Comparison
- Cabergoline (CBG)-treated vs treatment-naive PRLomas
- CBG-treatedn = 3
- Treatment-naiven = 2reference
- Outcome
- Cellular composition and transcriptional landscape
Methodological detailssingle-cell RNA sequencing
- Single-cell RNA sequencing
Main finding
As reported in the abstract
- Tumor cells
- 88.2%
- Immune cells
- 5.6%
- Stromal cells
- 4.9%
- Progenitor cells
- 0.6%
- Proliferating cells
- 0.4%
- Erythrocytes
- 0.2%
Original publication
Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis. Eur J Endocrinol. Published 23 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →